ArticleFrontiers in immunology2025

Efficacy and safety of programmed cell death protein-1 inhibitor for first-line therapy of advanced gastric or gastroesophageal junction cancer: a network meta-analysis.

Yunnan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.